Nucleos(t)ide analogue treatment reduces apoptotic activity in patients with chronic hepatitis B

Farnik, Harald; Lange, Christian; Hofmann, Wolf Peter; Berger, Annemarie; Allwinn, Regina; Welker, Martin-Walter; Trojan, Jörg; Sarrazin, Christoph; Herrmann, Eva; Zeuzem, Stefan; Kronenberger, Bernd

doi:10.1016/j.jcv.2011.08.009

Cited by 14 publications

(12 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, the World Health Organization (WHO) launched the first Global Hepatitis Report which sets out the big challenge in the management of the HBV population. The extremely low rate of diagnosed (9%) and low rate of treated patients (0.7%) in the 257 million estimated HBV carriers worldwide are the two major problems that we are facing in reducing HBV‐related death . It is critically important to screen patients who would benefit from antiviral treatment.…”

Section: Introductionmentioning

confidence: 99%

“…The extremely low rate of diagnosed (9%) and low rate of treated patients (0.7%) in the 257 million estimated HBV carriers worldwide are the two major problems that we are facing in reducing HBV-related death. 11 It is critically important to screen patients who would benefit from antiviral treatment. In this regard, general surveys or identification of patients with significant intrahepatic fibrosis is very important.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of serum Golgi protein 73 as a biomarker for the diagnosis of significant fibrosis in patients with chronic HBV infection

Wang

Liu

et al. 2017

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Transient elastography (TE) is accurate in staging fibrosis noninvasively. However, a reliable serum biomarker with comparable accuracy is also important, especially when TE is unreliable/unavailable. Therefore, we aimed to evaluate the diagnostic performance of serum Golgi protein 73 (GP73) for significant fibrosis in patients with chronic HBV infection. A total of 801 patients with chronic liver disease (CLD; 492 chronic HBV infection and 309 non-HBV liver disease) with liver biopsy performance were enrolled. Healthy controls (n = 180) and hepatocellular carcinoma (HCC) patients (n = 85) were included for comparisons. Liver biopsy was used as the reference method for fibrosis staging. Serum GP73 level was measured in duplicate in double-blind fashion. Serum GP73 was highest in HCC but also significantly higher in chronic hepatitis B than in healthy controls. The elevation of serum GP73 in non-HCC patients was significantly associated with the presence of significant fibrosis independently of ALT level, liver stiffness (LS) value, inflammation grade and other confounding factors. The diagnostic performance of serum GP73 was accurate in antiviral-naïve HBV patients (area under the receiver operating curve [AUROC], 0.76 95% CI: 0.72-0.81) but not in patients with ongoing antiviral treatment (AUROC, 0.60). The utility of serum GP73 was also confirmed in non-HBV CLD (AUROC, 0.80 95% CI: 0.75-0.85). Serum GP73 was comparable to LS (AUROC, 0.78 95% CI: 0.73-0.82) and significantly better than AST to platelet ratio index (APRI) (AUROC, 0.67 95% CI: 0.62-0.72) and FIB-4 (AUROC, 0.68 95% CI: 0.63-0.73). In conclusion, serum GP73 is an accurate serum marker for significant fibrosis in chronic HBV infection, with higher accuracy than APRI and FIB-4. Serum GP73 is potentially a complementary tool for TE when evaluating the necessity of antiviral treatment, particularly in patients without definite antiviral indication.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Assessment of serum Golgi protein 73 as a biomarker for the diagnosis of significant fibrosis in patients with chronic HBV infection

Wang

Liu

et al. 2017

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…In einer Pilotstudie von Patienten mit HBV-induziertem Leberversagen wurde durch eine antivirale Therapie nicht nur die Viruslast reduziert, sondern auch die Zelltodrate der Hepatozyten gesenkt [22]. In einer weiteren Studie war eine Abnahme der M30-und M65-Serumkonzentrationen mit dem virologischem Ansprechen auf eine Nukleos(t)id-Analoga-Therapie bei chronischer HBV-Infektion assoziiert [23].…”

unclassified

Zytokeratin-18 als Marker zur nichtinvasiven Diagnostik und Prognose akuter und chronischer Lebererkrankungen

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In another investigation carried out by Farnik et al with analogs of nucleotides and nucleosides, the M-30 apoptosis epitope and its quantitative levels before and after treatment were evaluated, and a significant decrease in HBV DNA parallel to qHBsAg was observed at the 24th week of treatment. M30-apoptotic activity was also significantly correlated with M65-necrosis and fibrosis (32). With this result, the study took its place in the medical literature as showing declined cell death parameters in relation to a decrease in HBV-DNA and HBsAg levels, indicating a reduction in overall cell death activity during treatment and supporting the idea that response to oral antiviral therapy reduces necroinflammatory activity and the progression of liver disease (32).…”

mentioning

confidence: 70%

“…M30-apoptotic activity was also significantly correlated with M65-necrosis and fibrosis (32). With this result, the study took its place in the medical literature as showing declined cell death parameters in relation to a decrease in HBV-DNA and HBsAg levels, indicating a reduction in overall cell death activity during treatment and supporting the idea that response to oral antiviral therapy reduces necroinflammatory activity and the progression of liver disease (32). qHBsAg levels and hepatocellular carcinoma: In the medical literature, it has been shown that qHBsAg may be used as an indicator for evaluating the risk of HCC occurrence.…”

mentioning

confidence: 84%

Clinical Usefulness of HBsAg Quantification in Patients with Chronic Hepatitis B Infection

Karagöz

Tanoğlu

2017

Hepat Mon

View full text Add to dashboard Cite

Context: Quantitative hepatitis B surface antigen (qHBsAg) levels have been shown to assist the management of patients with chronic hepatitis B virus (HBV) infection and reflect the level of transcriptional activity of covalently closed circular DNA (cccDNA). It has been indicated the importance of co-operative use of qHBsAg and HBV-DNA for diagnosis and monitoring of CHB treatment. Evidence Acquisition: In order to achieve a comprehensive approach in HBsAg quantification, an extensive search was done using relevant keywords in major medical libraries to collect, categorize, and summarize data in different sections. Results: A combination of qHBsAg < 1000 IU/mL and HBV-DNA < 2000 IU/mL can identify inactive carriers. qHBsAg levels are changed during the natural history of HBV infection that progressively declines from the immune tolerance to the inactive phase. Conclusions:The use of qHBsAg in chronic hepatitis B (CHB) patients may bring about important complementary information regarding HBV DNA during treatment and help predict the treatment outcome.

show abstract

Nucleos(t)ide analogue treatment reduces apoptotic activity in patients with chronic hepatitis B

Cited by 14 publications

References 23 publications

Assessment of serum Golgi protein 73 as a biomarker for the diagnosis of significant fibrosis in patients with chronic HBV infection

Assessment of serum Golgi protein 73 as a biomarker for the diagnosis of significant fibrosis in patients with chronic HBV infection

Zytokeratin-18 als Marker zur nichtinvasiven Diagnostik und Prognose akuter und chronischer Lebererkrankungen

Clinical Usefulness of HBsAg Quantification in Patients with Chronic Hepatitis B Infection

Contact Info

Product

Resources

About